Acceleron Pharma Inc. (NASDAQ:XLRN) finished Thursday with an addition of $0.04 to close at $175.33, an upside of 0.02 percent. An average of 1,951,360 shares of common stock have been traded in the last five days. There was a gain of $3.23 in the past week. The last 20 days have seen an average of 1,877,595 shares traded, while the 50-day average volume stands at 879,176.
XLRN stock has increased by 35.38% in the last month. The company shares reached their 1-month lowest point of $127.42 on 09/08/21. With the stock rallying to its 52-week high on 09/29/21, shares of the company touched a low of $99.98 and a high of $189.99 in 52 weeks. In spite of this, the price is down -7.72% from the 52-week high.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
11 days have passed since Acceleron Pharma Inc. (XLRN) last reported insider trading activity. KANGO SUJAY, who is EVP, Chief Commercial Officer, most recently acquired $5,000 shares at $175.00 per share on Sep 27. In this transaction, the insider spent $875,000. SVP, CFO and Treasurer, MCLAUGHLIN KEVIN F, disposed of 5,370 shares at a price of $160.38 on Sep 24. The insider now owns more than $861,241 worth of shares. Prior to that, SVP, CFO and Treasurer MCLAUGHLIN KEVIN F went on to Sale 19,630 shares at $160.31 each on Sep 23. An amount of $3,146,887 was transacted.
Acceleron Pharma Inc. (XLRN) has a trailing price-to-earnings (P/E) ratio of 34.65 for the broader industry and 32.11 for the sector. This means investors are optimistic about the stock’s future prospects. The stock’s beta is 0.22. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 104.24, the price-to-book (PB) ratio at 13.95.
The quick ratio of Acceleron Pharma Inc. for the three months ended June 29 was 12.10, and the current ratio was 12.10, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 For the recent quarter ending June 29. Acceleron Pharma Inc.’s EBITDA margin for the year ending June 29 is -176.67%. Its gross profit as reported stood at $259.83 million compared to revenue of $92.52 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Acceleron Pharma Inc.’s return on assets was -24.90%, compared to -30.1% over the last five years. In the past year, the return on investment has been -19.60%, and the 5-year average is -33.9%. Meanwhile, the return on equity (ROE) for the past 12 months has been -26.90% and the 5-year average holds at -33.2%. For the broader industry, ROE averaged -68.79 over the past year.
For the three-month period that ended June 29, Acceleron Pharma Inc. had $287.15 million in cash. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of $27.94 million in the quarter, while revenues of $24.76 million were shrunk -42.27%. The analyst consensus anticipated Acceleron Pharma Inc.’s latest quarter earnings to come in at -$0.87 per share, but it turned out to be -$1.05, a -20.70% surprise. For the recent quarter, EBITDA amounted to -$62.63 million. Shareholders own equity worth $60.9 million.
From a technical analysis perspective, let’s take a brief look at Acceleron Pharma Inc. (XLRN) price momentum. RSI 9-day as of the close on 07 October was 72.13%, suggesting the stock is Overbought, with historical volatility in this time frame at 44.04%.
As of today, XLRN’s price is $175.36 +1.88% or $3.23 from its 5-day moving average. XLRN is currently trading +33.87% higher than its 20-day SMA and +39.04% higher than its 100-day SMA. However, the stock’s current price level is +40.55% above the SMA50 and +31.13% above the SMA200.
The stochastic %K and %D were 75.63% and 75.75%, respectively, and the average true range (ATR) was 5.36. With the 14-day stochastic at 73.35% and the average true range at 5.42, the RSI (14) stands at 73.79%. The stock has reached -0.29 on the 9-day MACD Oscillator while the 14-day reading was at 7.30.
Jefferies launched coverage on Acceleron Pharma Inc. (NASDAQ: XLRN) in its analyst report released on October 07, 2021. The firm assigned the stock a a Hold rating.The consensus rating for Acceleron Pharma Inc. (XLRN) among analysts is Hold. According to current brokerage recommendations, 0 brokerage firms advise that investors sell XLRN, while 9 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 2 others rate it as a “buy”.
What is XLRN’s price target for the next 12 months?
Analysts predict a range of price targets between $160.00 and $180.00, with a median target of $180.00. Taking a look at these predictions, the average price target given by analysts for Acceleron Pharma Inc. (XLRN) stock is $177.36.